News

Novo Nordisk's Sales Increased By 19% In Danish Kroner And By 18% At Constant Exchange Rates To DKK 78.1 Billion In The First Three Months Of 2025
Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still expects ...